What is the Current Role of Taxanes in the Treatment of Metastatic Prostate Cancer?

Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]

Taxane-Based Chemotherapy Drugs May Be Underestimated, Especially Against Advanced Prostate Cancer

According to researchers at Weill Cornell Medical College in the Sept. 15 issue of the journal Cancer Research, taxne-based chemotherapy drugs are not well understood as they may be more powerful than many have believed. Generally, it is believed that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just stop a cancer cell from dividing -- but [...]

By |2012-09-18T12:41:03-04:00September 18th, 2012|Advanced Prostate Cancer,